Can You Master MASH Diagnosis and Management?
CME Jeopardy™
A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis.
Harrison SA, Bedossa P, Guy CD, et al. N Engl J Med. 2024;390(6):497-509.
Tirzepatide once weekly for the treatment of obesity.
Jastreboff AM, Aronne LJ, Ahmad NN, et al. N Engl J Med. 2022;387(3):205-216.
Efficacy of the glucagon-like peptide-1 receptor agonists liraglutide and semaglutide for the treatment of weight regain after bariatric surgery: a retrospective observational study.
Jensen AB, Renström F, Aczél S, et al. Obes Surg. 2023;33(4):1017-1025.
Resmetirom: an orally administered, small molecule, liver-directed, β-selective THR agonist for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
Karim G, Bansal MB. touchREV Endocrinol. 2023;19(1):60-70.
Impacts of cardiometabolic risk factors and alcohol consumption on all-cause mortality among MASLD and its subgroups.
Li M, Chen W, Deng Y, Xie W. Nutr Metab Cardiovasc Dis. 2024;34(9):2085-2094.
Semaglutide 2.4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial.
Loomba R, Abdelmalek MF, Armstrong MJ, et al. Lancet Gastroenterol Hepatol. 2023;8(6):511-522.
Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis.
Loomba R, Hartman ML, Lawitz EJ, et al. N Engl J Med. 2024;391(4):299-310.
Expert panel recommendations: practical clinical applications for initiating and monitoring resmetirom in patients with MASH/NASH and moderate to noncirrhotic advanced fibrosis.
Noureddin M, Charlton MR, Harrison SA, et al. Clin Gastroenterol Hepatol. 2024:S1542-3565(24)00667-0.
Monitoring disease progression in metabolic dysfunction-associated steatotic liver disease.
Noureddin N, Copur-Dahi N, Loomba R. Aliment Pharmacol Ther. 2024;59(suppl 1):S41-S51.
Persistence of severe liver fibrosis despite substantial weight loss with bariatric surgery.
Pais R, Aron-Wisnewsky J, Bedossa P, et al. Hepatology. 2022;76(2):456-468.
A multisociety Delphi consensus statement on new fatty liver disease nomenclature.
Rinella ME, Lazarus JV, Ratziu V, et al. Hepatology. 2023;78(6):1966-1986.
Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis.
Sanyal AJ, Newsome PN, Kliers I, et al. N Engl J Med. 2025. [Epub ahead of print]
Once-weekly semaglutide in adults with overweight or obesity.
Wilding JPH, Batterham RL, Calanna S, et al. N Engl J Med. 2021;384(11):989-1002.
Epidemiology of metabolic dysfunction-associated steatotic liver disease.
Younossi ZM, Kalligeros M, Henry L. Clin Mol Hepatol. 2025;31(Suppl):S32-S50.
Downloadable Resource
A Clinician's Pocket Guide to MASH Diagnosis and Management
Download and print this free clinician's resource
Clinical Practice Guidelines
Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD Practice Guidance.
Chen VL, Morgan TR, Rotman Y, et al. Hepatology. 2025;81(1):312-320.
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease.
Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. Hepatology. 2023;77(5):1797-1835.
AASLD Practice Guideline on imaging-based non-invasive liver disease assessments of hepatic fibrosis and steatosis.
Sterling RK, Duarte-Rojo A, Patel K, et al. Hepatology. 2024. [Epub ahead of print]
Clinical Resources
Fibrosis-4 (FIB-4) index for liver fibrosis.
Resmetirom prescribing information.
US Food and Drug Administration.
Can You Master MASH Diagnosis and Management?
A CME Jeopardy™ On Demand Activity
| Faculty: | Sonal Kumar, MD, MPH; Mazen Noureddin, MD, MHSc; Kymberly D. Watt, MD |
| Release: | 05/03/2025 |
| Expiration: | 06/03/2026 |
